1.Implementation and clinical application of hypertonia assessment tool
Beibei KANG ; Zhihai LYU ; Lei XU ; Yanping FAN ; Zhimei JIANG
Chinese Journal of Applied Clinical Pediatrics 2015;(14):1117-1118
As the urgent need of both clinic and research,the identification of hypertonia subtypes is becoming more and more important. Hypertonia assessment tool is a standardized discriminative measure with good reliability and validity. Hypertonia assessment tool can identify paediatric hypertonia subtypes. For its easily learning,it can be easily generalized in clinician.
2.Genetic abnormalities and their relationship with the clinical features in pediatric Burkitt lymphoma
Miao WANG ; Liya SU ; Wenping YANG ; Beibei LYU ; Liping GONG
Journal of Leukemia & Lymphoma 2013;22(4):197-201
Objective To analyze the molecular cytogenetic abnormalities and pathogenesis of pediatric Burkitt lymphoma (BL) by array comparative genomic hybridization (aCGH).Methods First,immunophenotype,molecular genetics and EB virus (EBV) infection status were detected using immunohistochemistry and fluorescence in situ hybridization in 21 pediatric BL patients.Second,in addition to detecting genome-wide genetic gain/deletion status,aCGH results with EBV infection status were also correlated.Results aCGH results showed genetic alterations in 19 cases (90.5 %).Generally,frequency of chromosomal gain was higher than chromosomal deletion.The regions of frequently-occurring small DNA genomic fragment gains (≥40 % cases) were 3q21.1,5p13.2,19q13.32,12q23.1,14q32.33,6q27,20p13 and 20p11.21.Large DNA fragment gains and deletions could be detected in 42.9 % (9/21) cases in the 14q24.2 and 14q32.33 regions.There was no significant difference in genetic alterations between EBV (+) and EBV (-) BL cases (P≥0.05).Conclusion aCGH results show that BL cases have complex genetic alterations,which have no significant difference between EBV(+) and EBV(-) cases.Most BL cases show large DNA segment deletion or acquisition of 14q,indicating that 14q gene alteration plays an important role in the pathogenesis of BL.
3.Expressions of leptin receptor and phosphorylated protein kinase B in diffuse large B-cell lymphoma and its significance
Lin SONG ; Beibei LYU ; Dongsheng HOU ; Yazhou ZHANG
Journal of Leukemia & Lymphoma 2020;29(6):331-334
Objective:To investigate the expressions of leptin receptor (OBR) and phosphorylated protein kinase B (p-AKT) in patients with diffuse large B-cell lymphoma (DLBCL) and its significance.Methods:Immunohistochemistry was applied to detect the expressions of OBR and p-AKT in tissues from 90 patients with DLBCL and 20 patients with reactive lymphoid hyperplasia (RLH) between 2010 and 2015 in Shandong Provincial Hospital Affiliated to Shandong First Medical University. Cell proliferation assay was used to detect the effect of leptin on the proliferation of SUDHL4 and SUDHL5 in DLBCL cell lines, and the expression of p-AKT in SUDHL4 and SUDHL5 after the cultured leptin was detected by using Western blot.Results:The high expression rate of OBR and p-AKT of DLBCL was 47.7% (43/90) and 27.7% (25/90), respectively, and low expression was found in 20 cases of RLH. There were statistically differences in the expressions of OBR and p-AKT in DLBCL and RLH ( P < 0.01, P = 0.027). The expressions of OBR and p-AKT were not correlated with age, gender, extranodal infiltrations, clinical staging, lactic dehydrogenase (LDH) level, B-symptom and international prognostic index (IPI) score (all P > 0.05). The expression of OBR was positively related with that of p-AKT in DLBCL patients ( r = 0.532, P < 0.05). Leptin could increase the proliferation of SUDHL4 and SUDHL5 cells and promote the expression of p-AKT. Conclusion:Leptin and OBR can promote the proliferation of DLBCL cells and may be involved in the occurrence and development of DLBCL by activating PI3K-AKT pathway.
4.Clinical, pathological and gene variation characteristics of 16 patients with chronic progressive external ophthalmoplegia
Yaguang ZHOU ; Qianqian QU ; Xianzhao ZHENG ; Xiaoli MA ; Wenhao CUI ; Zheng LYU ; Haiyan LIU ; Beibei CAO ; Haidong LYU
Chinese Journal of Neuromedicine 2022;21(9):897-904
Objective:To investigate the clinical characteristics, skeletal muscle pathologies and gene variations of chronic progressive external ophthalmoplegia (CPEO).Methods:Sixteen patients with conformed CPEO, admitted to our hospital from January 1997 to December 2021, were chosen. Their clinical data such as onset age and course of diseases and muscle pathological examination results were collected and their gene variation characteristics were analyzed.Results:The initial symptom in all 16 patients was ptosis of varying degrees; 15 patients were with eye movement disorder, 6 with diplopia, 4 with proximal limb weakness, and 3 with dysphagia and dysarthria. Among the 16 patients, electromyography showed myogenic damage in 7 patients, myogenic combined with neurogenic damage in 1 patient, neurogenic damage in 1 patient, and normal in 7 patients. Skeletal muscle biopsies indicated that 14 patients were with ragged red fibers (RRF), 11 patients had cytochrome C oxidase (COX)-negative muscle fibers, 3 patients had a small amount of degenerated and necrotic myofibers with mononuclear phagocytic infiltration. Immunohistochemical staining indicated infiltration of CD8 and CD68 positive lymphocytes. Ten patients accepted genetic test, indicating 6 patients with single large fragment deletion of mitochondrial DNA (mtDNA), 1 patient with mtDNA point mutation, 1 patient with nucleosomal DNA (nDNA) point mutation, and 2 patients without pathogenicity variation clearly associated with clinical phenotype. Electron microscopy in 5 patients showed that abnormal mitochondrial aggregation was noted in 4 patients under the sarcolemma and among the myofibrils.Conclusion:In addition to ptosis and eye movement disorders, a small number of patients with CPEO may be accompanied by dysphagia and limb weakness; and single large fragment deletion of mtDNA is the main mutation form of CPEO.
5.Clinical, pathological and gene variation characteristics of 16 patients with chronic progressive external ophthalmoplegia
Yaguang ZHOU ; Qianqian QU ; Xianzhao ZHENG ; Xiaoli MA ; Wenhao CUI ; Zheng LYU ; Haiyan LIU ; Beibei CAO ; Haidong LYU
Chinese Journal of Neuromedicine 2022;21(9):897-904
Objective:To investigate the clinical characteristics, skeletal muscle pathologies and gene variations of chronic progressive external ophthalmoplegia (CPEO).Methods:Sixteen patients with conformed CPEO, admitted to our hospital from January 1997 to December 2021, were chosen. Their clinical data such as onset age and course of diseases and muscle pathological examination results were collected and their gene variation characteristics were analyzed.Results:The initial symptom in all 16 patients was ptosis of varying degrees; 15 patients were with eye movement disorder, 6 with diplopia, 4 with proximal limb weakness, and 3 with dysphagia and dysarthria. Among the 16 patients, electromyography showed myogenic damage in 7 patients, myogenic combined with neurogenic damage in 1 patient, neurogenic damage in 1 patient, and normal in 7 patients. Skeletal muscle biopsies indicated that 14 patients were with ragged red fibers (RRF), 11 patients had cytochrome C oxidase (COX)-negative muscle fibers, 3 patients had a small amount of degenerated and necrotic myofibers with mononuclear phagocytic infiltration. Immunohistochemical staining indicated infiltration of CD8 and CD68 positive lymphocytes. Ten patients accepted genetic test, indicating 6 patients with single large fragment deletion of mitochondrial DNA (mtDNA), 1 patient with mtDNA point mutation, 1 patient with nucleosomal DNA (nDNA) point mutation, and 2 patients without pathogenicity variation clearly associated with clinical phenotype. Electron microscopy in 5 patients showed that abnormal mitochondrial aggregation was noted in 4 patients under the sarcolemma and among the myofibrils.Conclusion:In addition to ptosis and eye movement disorders, a small number of patients with CPEO may be accompanied by dysphagia and limb weakness; and single large fragment deletion of mtDNA is the main mutation form of CPEO.
6.Clinical, imaging and pathological features of duodenal gangliocytic paraganglioma
Jizhen FENG ; Zhigang YAO ; Beibei LYU ; Chang LU ; Jiamei LI
Chinese Journal of Hepatobiliary Surgery 2022;28(7):531-535
Objective:To study the clinical, imaging and pathological features of duodenal gangliocytic paraganglioma (DGP).Methods:The clinical, imaging and pathological data of patients with DGP treated at the Shandong Provincial Hospital Affiliated to Shandong First Medical University from January 2012 to October 2021 were retrospectively analyzed.Results:Of 8 patients with DGP, there were 7 males and 1 female, with a median age of 52 years (range 37 to 57 years). Five patients were asymptomatic and they were diagnosed on physical examination followed by investigations. Three patients presented with black stools. CT examination showed localized nodular thickening of the duodenum, with enhanced scanning showing obvious progressive contrast enhancement. Endoscopic ultrasonography showed a hypoechoic submucosal lesion in duodenal wall. Histologically, the neoplasm composed of three different cell types which included Schwann cells, epithelioid cells, and ganglioid cells. The Schwann cells expressed NF, NSE and S-100 proteins; the epithelioid cells expressed CK, NSE, Syn and CgA proteins; while the ganglioid cells expressed NSE, Syn, CgA and NF proteins. Endoscopic submucosal dissection was performed in 2 patients and surgical resection was performed in 6 patients.Conclusion:DGP is a rare benign neurogenic tumor which is most commonly found in the duodenum. It has a good prognosis. Imaging and endoscopic examinations demonstrated a submucosal mass. The main treatment are endoscopic resection and local surgical resection.
7.Interpretation on physical therapy management of children with developmental coordination disorder: an evidence-based clinical practice guideline from the Academy of Pediatric Physical Therapy of the American Physical Therapy Association in 2020
Zhen LYU ; Meihuan HUANG ; Beibei KANG ; Yanping FAN ; Peifu ZOU ; Jianguo CAO ; Zhimei JIANG ; Xiaoyan SHEN ; Qian ZHANG ; Jiaqin WANG
Chinese Journal of Applied Clinical Pediatrics 2021;36(22):1710-1715
Developmental coordination disorder (DCD) is a childhood-onset condition that primarily affects physical co-ordination.In China, DCD is not well recognized and is under-treated.Knowledge of the evaluation and intervention of DCD among physiotherapists (PT) is limited.In 2020, the Academy of Pediatric Physical Therapy of the American Physical Therapy Association published the Physical Therapy Management of Children with Developmental Coordination Disorder: An Evidence-Based Clinical Practice Guideline.From the perspective of PT, this review aims to make a comprehensive interpretation of the recommendations in the guideline regarding the physical examination and evaluation, physiotherapy planning and implementation, and family education of children at risk or diagnosed with DCD.This article aims to make DCD get more attention from domestic PT through the interpretation of the latest guidelines, and strengthen the knowledge of physiotherapy assessment and management in children with DCD to guide the clinical practice.
8.Method establishment for content determination of related substances in Oxcarbazepine tablets
Minmin BAO ; Beibei LYU ; Wenzhi WEI ; Minjuan ZHANG
China Pharmacy 2023;34(10):1199-1203
OBJECTIVE To establish the method for content determination of related substances in Oxcarbazepine tablets. METHODS Ultra-high performance liquid chromatography (UPLC) method was adopted and the separation was performed on ZORBAX Eclipse Plus C18 column with mobile phase consisted of acetonitrile-0.01 mol/L ammonium acetate solution (pH6.0) (gradient elution) at the flow rate of 0.5 mL/min. The detection wavelength was 230 nm and column temperature was set at 35 ℃. The sample size was 10 μL. RESULTS The linear ranges of oxcarbazepine and impurity A, B, C, D, E, I, K, L and N were 0.192-1.440, 1.019-7.639, 0.208-1.559, 0.230-1.727, 0.389-2.915, 0.182-1.364, 0.393-2.945, 0.199-1.493, 0.199-1.490 and 0.200- 1.503 μg/mL, respectively (all r>0.999). The detection limits were 0.046, 0.037, 0.049, 0.027, 0.077, 0.040, 0.114, 0.054, 0.055 and 0.039 μg/mL. The quantitation limits were 0.152, 0.122, 0.162, 0.090, 0.258, 0.132, 0.380, 0.181, 0.185 and 0.130 μg/mL. RSDs of precision, repeatability, stability (24 h) and durability tests were all lower than 5.0%. The average recoveries were 92.8%-105.6% (RSD≤3.0%, n=9). Only impurity K and unknown impurity were detected in the original preparation sample, with a total content of 0.078% to 0.083%; impurities A, B, D, I and unknown impurity were detected in the generic preparations produced by domestic enterprise Ⅰ, with a total content of 0.147% to 0.163%; impurities A, B, I and unknown impurity were detected in the generic preparations produced by domestic enterprise Ⅱ, with a total content of 0.085% to 0.161%. CONCLUSIONS The established method is rapid, sensitive, accurate, stable and durable. It can be used for the content determination of 9 known impurities in Oxcarbazepine tablets.
9.Consistency Evaluation on the Dissolution Behavior and Related Indicators between Generic and Original Pre- parations of Oxcarbazepine Scored Tablets
Beibei LYU ; Haiyuan YANG ; Hua CHENG ; Wenzhi WEI ; Minjuan ZHANG
China Pharmacy 2020;31(12):1463-1458
OBJECTIVE:To evaluate the dissolution behavior consistency between the generic drugs and original drugs of Oxcarbazepine scored tablets ,and to compare the appearance ,the friability of the split portions ,loss of mass of the split portions as well as crystal form and morphology of raw material from different enterprises. METHODS :HPLC method was adopted. The paddle method (rotation speed of 60 r/min,the temperature of 37.0℃)was adopted to determine accumulative dissolution rate of generic and original drugs in 4 mediums [ 0.6% SDS hydrochloric acid solution (pH=1.2),0.6% SDS acetate buffer solution (pH=4.5),0.6% SDS phosphate buffer solution (pH=6.8)and 0.6% SDS water solution]. The similarity factor method was used to evaluate the similarity of dissolution curves as well as intra-batch uniformity of the split portions and whole tablets. The friability tester and electronic balance were used to determine the friability and the loss of mass of the split portions. X-ray diffractometer and scanning electron microscope were used to observe the crystal form and crystal morpho logy of the raw materials of different enterprises. RESULTS :The linear range of oxcarbazepine was LOD was 0.04 μg/mL;RSDs of precision ,stability,reprodu- cibility and durability tests were lower than 2.0%;the reco- veries were 99.80%-101.63%(RSD=0.37%-0.91%,n=3). The average cumulati ve dissolution rate of generic drug A , generic drug B and original drug in 4 different dissolution media at 90 min were 92%,87%,90% [0.6% SDS hydrochloric acid solution(pH=1.2)];94%,94%,90% [0.6% SDS acetate buffer solution (pH=4.5)];95%,95%,91% [0.6% SDS phosphate buffer solution (pH 6.8)];97%,98%,95%(0.6% SDS water solution ). The similarity factors of generic drug A ,generic drug B and original drug in 4 kinds of different dissolution media were 66 and 81,71 and 69,71 and 61,59 and 39. In the first 15 min,the difference of dissolution rate of split portions and whole tablets were -3%-13%,-2%-24% and -3%-7% for generic drug A , generic drug B and original drug ,respectively. RSDs of accumulative dissolution rate of split portions and whole tablets were 6%-14% and 2%-9% for generic drug A (n=12),4%-10% and 1%-8% for generic drug B (n=12)and 2%-7% and 2%-8% for original drug. The appearance of the original drug was fusiform ,and the notch was deep ;the shape of the generic drug was different from each other ,and the notch of the generic drug was significantly shallower than that of original drug. The friability , the loss of mass of the split portions for generic drug A and generic drug B ,original drug were 0.62%and 0.67%,0.12% and 0.11%,0.08% and 0.05%. The domestic raw materials possessed irregular lumps and debris ,while the raw materials produced by original drug enterprises possessed regular flat cuboids and regular strips with little debris ;but X-ray diffraction peaks of them were basically the same. CONCLUSIONS :The dissolution behavior of generic drug A in 4 medium is consistent with that of the original drug;dissolution behavior of generic drug B in water containing 0.6%SDS is different from that of the original drug ;there is no significant change in the homogeneity of the original drug before and after splitting ,but the homogeneity of the generic drug A and B after splitting is lower than that of the whole tablet ;the fragility of generic drugs and loss of mass of split portions are higher than those of the original drugs ;two kinds of raw material have the same crystal form but different crystal morphology.